97 related articles for article (PubMed ID: 2050288)
1. Effect of the calmodulin antagonist CGS 9343B on skin burns.
Beitner R; Chen-Zion M; Bassukevitz Y
Gen Pharmacol; 1991; 22(1):67-72. PubMed ID: 2050288
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic and prophylactic treatment of skin burns with several calmodulin antagonists.
Beitner R; Chen-Zion M; Sofer-Bassukevitz Y; Oster Y; Ben-Porat H; Morgenstern H
Gen Pharmacol; 1989; 20(2):165-73. PubMed ID: 2714615
[TBL] [Abstract][Full Text] [Related]
3. CGS 9343B, a novel, potent, and selective inhibitor of calmodulin activity.
Norman JA; Ansell J; Stone GA; Wennogle LP; Wasley JW
Mol Pharmacol; 1987 May; 31(5):535-40. PubMed ID: 3033469
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of gastric acid secretion in vivo and in vitro by a new calmodulin antagonist, CGS 9343B.
Black EW; Strada SJ; Garrett RL; Kvietys PR; Thompson WJ; Norman JA
J Pharmacol Exp Ther; 1989 Jan; 248(1):208-14. PubMed ID: 2464057
[TBL] [Abstract][Full Text] [Related]
5. Influence of CGS 9343B, an inhibitor of calmodulin activity, on histamine release from isolated rat mast cells.
Grosman N
Agents Actions; 1992 Jul; 36(3-4):192-9. PubMed ID: 1382372
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cholera-toxin-stimulated intestinal secretion by CGS 9343B in rats: a specific calmodulin inhibitor.
Fedorak RN; Kotake A; Douglas F; Chang EB
J Pediatr Gastroenterol Nutr; 1989 Feb; 8(2):252-8. PubMed ID: 2540305
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of membrane currents and rises of intracellular Ca2+ in PC12 cells by CGS 9343B, a calmodulin inhibitor.
Neuhaus R; Reber BF
Eur J Pharmacol; 1992 Jun; 226(2):183-5. PubMed ID: 1379190
[TBL] [Abstract][Full Text] [Related]
8. The calmodulin inhibitor CGS 9343B inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells.
Li H; Hong DH; Kim HS; Kim HW; Jung WK; Na SH; Jung ID; Park YM; Choi IW; Park WS
Toxicol Appl Pharmacol; 2015 Jun; 285(3):207-13. PubMed ID: 25796172
[TBL] [Abstract][Full Text] [Related]
9. Calmodulin-dependent modulation of pH sensitivity of the amino acid transport system L in human placental choriocarcinoma cells.
Brandsch M; Leibach FH; Mahesh VB; Ganapathy V
Biochim Biophys Acta; 1994 Jun; 1192(2):177-84. PubMed ID: 8018698
[TBL] [Abstract][Full Text] [Related]
10. Novel calmodulin antagonist CGS 9343B inhibits secretory diarrhea.
Shook JE; Burks TF; Wasley JW; Norman JA
J Pharmacol Exp Ther; 1989 Oct; 251(1):247-52. PubMed ID: 2795459
[TBL] [Abstract][Full Text] [Related]
11. CGS 9343B and W7 (calmodulin antagonists) inhibit KCl-induced increase in cytosolic free calcium and insulin secretion of RINm5F cells.
Safayhi H; Kühn M; Koopmann I; Ammon HP
Naunyn Schmiedebergs Arch Pharmacol; 1989; 339(1-2):8-13. PubMed ID: 2657441
[TBL] [Abstract][Full Text] [Related]
12. Effects of CGS 9343B (a putative calmodulin antagonist) on isolated skeletal muscle. Dissociation of signaling pathways for insulin-mediated activation of glycogen synthase and hexose transport.
Shashkin P; Koshkin A; Langley D; Ren JM; Westerblad H; Katz A
J Biol Chem; 1995 Oct; 270(43):25613-8. PubMed ID: 7592735
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mechanotransducer currents in crayfish sensory neuron by CGS 9343B, a calmodulin antagonist.
Lin JH; Rydqvist B
Eur J Pharmacol; 2000 May; 397(1):11-7. PubMed ID: 10844093
[TBL] [Abstract][Full Text] [Related]
14. Treatment of frostbite with the calmodulin antagonists thioridazine and trifluoperazine.
Beitner R; Chen-Zion M; Sofer-Bassukevitz Y; Morgenstern H; Ben-Porat H
Gen Pharmacol; 1989; 20(5):641-6. PubMed ID: 2606333
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of voltage-gated Ca2+ channels and insulin secretion in HIT cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-62: comparison with antagonists of calmodulin and L-type Ca2+ channels.
Li G; Hidaka H; Wollheim CB
Mol Pharmacol; 1992 Sep; 42(3):489-8. PubMed ID: 1328847
[TBL] [Abstract][Full Text] [Related]
16. Improvement of ischemia-reperfusion-induced myocardial dysfunction by modulating calcium-overload using a novel, specific calmodulin antagonist, CGS 9343B.
Das DK; Engelman RM; Prasad MR; Rousou JA; Breyer RH; Jones R; Young H; Cordis GA
Biochem Pharmacol; 1989 Feb; 38(3):465-71. PubMed ID: 2917008
[TBL] [Abstract][Full Text] [Related]
17. A novel calmodulin antagonist, CGS 9343B, modulates calcium-dependent changes in neurite outgrowth and growth cone movements.
Polak KA; Edelman AM; Wasley JW; Cohan CS
J Neurosci; 1991 Feb; 11(2):534-42. PubMed ID: 1992015
[TBL] [Abstract][Full Text] [Related]
18. Effects of Ca(2+)-ionophore A23187 and calmodulin antagonists on regulatory mechanisms of glycolysis and cell viability of NIH-3T3 fibroblasts.
Ashkenazy-Shahar M; Beitner R
Mol Genet Metab; 1999 Aug; 67(4):334-42. PubMed ID: 10444344
[TBL] [Abstract][Full Text] [Related]
19. Treatment of muscle damage, induced by high intracellular Ca2+, with calmodulin antagonists.
Beitner R; Lilling G
Gen Pharmacol; 1993 Jul; 24(4):847-55. PubMed ID: 8224738
[TBL] [Abstract][Full Text] [Related]
20. Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells.
Glass-Marmor L; Morgenstern H; Beitner R
Eur J Pharmacol; 1996 Oct; 313(3):265-71. PubMed ID: 8911923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
